The historical rank and industry rank for Corbus Pharmaceuticals Holdings's EV-to-FCF or its related term are showing as below:
STU:3371'
s EV-to-FCF Range Over the Past 10 Years
Min: -43.93 Med: -1.41 Max: 1.22
Current: -0.54
During the past 13 years, the highest EV-to-FCF of Corbus Pharmaceuticals Holdings was 1.22. The lowest was -43.93. And the median was -1.41.
STU:3371's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.33
vs STU:3371: -0.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Corbus Pharmaceuticals Holdings's PE Ratio (TTM) for today is calculated as:
Corbus Pharmaceuticals Holdings's share price for today is €8.355.
Corbus Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.998.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Corbus Pharmaceuticals Holdings EV-to-FCF Related Terms
Corbus Pharmaceuticals Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3371 vs PRQR, NRXP, CRBU: EV-to-FCF Comparison
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's EV-to-FCF falls into.
Corbus Pharmaceuticals Holdings's current Enterprise Value is €34.90 Mil.
Corbus Pharmaceuticals Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-63.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings (STU:3371) has a EV-to-FCF of -0.55 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Corbus Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 330 companies in the Biotechnology industry.
Is Corbus Pharmaceuticals Holdings' EV-to-FCF too high?
Corbus Pharmaceuticals Holdings' current EV-to-FCF is -0.55. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' EV-to-FCF compare to PRQR and NRXP?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 330 companies for EV-to-FCF. This places Corbus Pharmaceuticals Holdings in the lower half of its industry. The industry median EV-to-FCF is 16.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.33, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Corbus Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corbus Pharmaceuticals Holdings's current EV-to-FCF is -0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Corbus Pharmaceuticals Holdings (STU:3371) has a current EV-to-FCF of -0.55. The current EV-to-FCF is -0.55. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current EV-to-FCF is -0.55 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corbus Pharmaceuticals Holdings Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score
Get the complete analysis for STU:3371
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3371 has been successfully added to your 
